Skip to main content
. 2015 Jun 20;6(6):699–707. doi: 10.1111/jdi.12370

Figure 5.

Figure 5

(a) Association between the average glucose level by continuous glucose monitoring (CGM) at baseline and the reduction in the average daily glucose concentration during the 7-day ipragliflozin treatment. (b) Association between the average glucose level of the CGM and 24-h urine glucose excretion on day 0 (closed circle) and on day 7 (open circle) of the ipragliflozin treatment.